Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Lianqi Liu"'
Autor:
Michelle Rissling, Lianqi Liu, Shawn D. Youngstedt, Vera Trofimenko, Loki Natarajan, Ariel B. Neikrug, Neelum Jeste, Barbara A. Parker, Sonia Ancoli-Israel
Publikováno v:
Frontiers in Neuroscience, Vol 18 (2024)
Externí odkaz:
https://doaj.org/article/bc33d51a2dd64f89b57cf6b36ba425c5
Publikováno v:
Drug Delivery, Vol 29, Iss 1, Pp 754-766 (2022)
Maleimides are typically applicable for coupling with reactive thiol moieties of antibodies in antibody–drug conjugates (ADCs) via the thiol-Michael click chemistry. Even so, the thiosuccinimide group produced in ADCs is unstable under physiologica
Externí odkaz:
https://doaj.org/article/187d77e0ab594658a0b85411d7c1f947
Autor:
Rui Hu, Bingbing Lai, Wenhao Ma, Yuan Zhang, Yujiao Deng, Lianqi Liu, Zeping Lv, Chetwyn Chan, Fan Zhang, Qian Tao
Publikováno v:
BMC Geriatrics, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background The current study investigated the relationship between behavioural and psychological symptoms of dementia (BPSD) knowledge and positive aspects of caregiving (PAC), in addition, how caregiving attitude and self-efficacy mediate o
Externí odkaz:
https://doaj.org/article/b3a5f6a5297d42b2aca9d167265d5f2e
Autor:
Rissling, Michelle, Lianqi Liu, Youngstedt, Shawn D., Trofimenko, Vera, Natarajan, Loki, Neikrug, Ariel B., Jeste, Neelum, Parker, Barbara A., Ancoli-Israel, Sonia
Publikováno v:
Frontiers in Neuroscience; 2024, p1-11, 11p
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3889-3907 (2021)
Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs. An ideal li
Externí odkaz:
https://doaj.org/article/c63ef4542405418fa2fd2886b82340e4
Autor:
Lianqi Liu, Fei Xie, Dian Xiao, Xin Xu, Zheng Su, Yanming Wang, Shiyong Fan, Xinbo Zhou, Song Li
Publikováno v:
Drug Delivery, Vol 28, Iss 1, Pp 2603-2617 (2021)
Camptothecins, traditional chemotherapy drugs, have been clinically used in antibody-drug conjugates (ADCs), which refreshes the recognition that ADCs preferably incorporate highly potent payloads. However, SN-38, active metabolite of irinotecan from
Externí odkaz:
https://doaj.org/article/734e26563ba54e77b224f0fa0e7f421c
Autor:
Michelle Rissling, Lianqi Liu, Shawn D. Youngstedt, Vera Trofimenko, Loki Natarajan, Ariel B. Neikrug, Neelum Jeste, Barbara A. Parker, Sonia Ancoli-Israel
Publikováno v:
Frontiers in Neuroscience, Vol 16 (2022)
PurposeThe goal of this study was to examine whether daily increased morning light exposure would maintain or improve sleep and the circadian pattern of relatively more activity in the day and less during the night in women undergoing chemotherapy fo
Externí odkaz:
https://doaj.org/article/212152495109466a83065dd7f6adc51d
Publikováno v:
Molecules, Vol 25, Iss 2, p 407 (2020)
In this article, we report the design, synthesis, photodynamic properties, and in vitro evaluation of photoactivatable prodrug for the poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor Talazoparib. In order to yield a photoactivatable, inactive prodr
Externí odkaz:
https://doaj.org/article/6c902842914b46d6a34868505f38f965
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3889-3907 (2021)
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3889-3907 (2021)
Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs. An ideal li
Autor:
Sonia Ancoli-Israel, Lianqi Liu, Loki Natarajan, Michelle Rissling, Ariel B. Neikrug, Shawn D. Youngstedt, Paul J. Mills, Georgia R. Sadler, Joel E. Dimsdale, Barbara A. Parker, Barton W. Palmer
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol 30, iss 4
Purpose To examine long-term cognitive effects of chemotherapy and identify predictors among women with breast cancer (WBC). Patients and methods Sixty-nine WBC scheduled to receive chemotherapy, and 64 matched-controls with no cancer, participated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2278719d341e156b92ec8a8eeba4d175
https://escholarship.org/uc/item/4rt3r2jw
https://escholarship.org/uc/item/4rt3r2jw